Education
About Us
Working with TipRanks
Follow Us
Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
COYA Stock Chart & Stats
$4.69
-$0.10(-1.62%)
At close: 4:00 PM EST
$4.69
-$0.10(-1.62%)
Day’s Range― - ―
52-Week Range$3.94 - $7.86
Previous CloseN/A
Volume16.99K
Average Volume (3M)266.35K
Market Cap
$98.14M
Enterprise Value$53.54M
Total Cash (Recent Filing)$28.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 24, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding20,924,456
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)2.21
Price to Sales (P/S)24.57
P/FCF Ratio-8.49
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue13.43
Enterprise Value/Gross Profit-16.85
Enterprise Value/Ebitda-2.68
Forecast
1Y Price Target
$17.00Price Target Upside262.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.49
Revenue Forecast (FY)$1.92M
Bulls Say, Bears Say
Bulls Say
Funding And Partner SupportPatient dosing in the ALSTARS Phase 2 ALS trial triggered a partner milestone payment and recent equity financing strengthened cash resources, improving funding visibility for ongoing development.
Mechanism And Biomarker EvidenceInvestigator-sponsored data showed clear target engagement with sustained increases in regulatory T-cell numbers and suppressive function, supporting the drug's mechanism against harmful neuroinflammation.
Regulatory MilestoneFDA acceptance of an Investigational New Drug application for the lead candidate enables initiation of U.S. clinical development in frontotemporal dementia and opens a regulatory pathway toward later-stage trials.
Bears Say
High Indication Failure RiskTherapeutic development in ALS has a high historical failure rate, so early positive signals may not translate into successful pivotal outcomes.
Regulatory, Commercial And Partnership RiskFailure to advance into pivotal development or to obtain U.S. regulatory approval, along with weak commercial uptake or partner setbacks, could materially reduce the company's valuation and prompt additional equity dilution.
Study Size And DurationInvestigator-initiated studies involved very small patient numbers and likely insufficient follow-up to demonstrate disease‑modifying effects, leaving clinical benefit unproven.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.94 and its highest was $7.86 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $98.14M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Mar 24, 2026 which is in 19 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Sep 30, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.233 by $0.103.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.27.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 20,924,456 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.233. Following the earnings report the stock price went up 0.707%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coya Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (262.47% Upside)
$17.00 (262.47% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.31%
12-Months-Change
Fundamentals
Return on Equity
-62.18%
Trailing 12-Months
Asset Growth
-9.87%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$17.00
▲(262.47% Upside)
Technical Analysis
Ownership Overview
4.95% Insiders
4.25% Mutual Funds
26.61% Other Institutional Investors
59.97% Public Companies and
Individual Investors